PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Dabigatran	15-25	adenomatous polyposis coli protein	Oryctolagus cuniculus	87-106
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Dabigatran	15-25	adenomatous polyposis coli protein	Oryctolagus cuniculus	108-111
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Rivaroxaban	30-41	adenomatous polyposis coli protein	Oryctolagus cuniculus	87-106
35128064-3	2022	The effects of dabigatran and rivaroxaban on the activities of FII, FV, FVIII, FX, and activated protein C (APC) were analyzed.	Rivaroxaban	30-41	adenomatous polyposis coli protein	Oryctolagus cuniculus	108-111
35128064-5	2022	Low doses of dabigatran inhibited APC activity.	Dabigatran	13-23	adenomatous polyposis coli protein	Oryctolagus cuniculus	34-37
35128064-10	2022	Low concentrations of dabigatran generated an inhibitory effect on APC activity, while high concentrations of dabigatran had no significant effect.	Dabigatran	22-32	adenomatous polyposis coli protein	Oryctolagus cuniculus	67-70